Prodotti competitors / Area Oncology 21 marzo 2025 FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
Prodotti competitors / Area Kite 21 marzo 2025 BMS: Commissione Europea approva liso-cel nel trattamento del linfoma follicolare
Prodotti competitors / Area Kite 21 marzo 2025 Removal of orphan designation status for Glofitamab in Europe
Prodotti competitors / Area Oncology 21 marzo 2025 FDA granted traditional approval to Keytruda for HER2+PD-L1+ gastric or GEJ adenocarcinoma
Prodotti competitors / Area Onco-Ema, Area Kite 28 febbraio 2025 The CHMP recommended granting a conditional marketing authorisation for Lynozyfic (linvoseltamab) for the treatment of patients with relapsed and refractory multiple myeloma
Prodotti competitors / Area Onco-Ema, Area Kite 28 febbraio 2025 Columvi (glofitamab) : CHMP opinion on variation to marketing authorisation in relapsed or refractory diffuse large B-cell lymphoma
Prodotti competitors / Area Oncology 28 febbraio 2025 Enhertu (trastuzumab deruxtecan): CHMP opinion on variation to marketing authorisation in HR-positive HER2-low or -ultralow breast cancer
Prodotti competitors / Area Onco-Ema, Area Kite 28 febbraio 2025 J&J’s DARZALEX (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Prodotti competitors / Area Oncology 26 febbraio 2025 New Merck Phase 3 trial (TroFuse-011) assessing sacituzumab tirumotecan ± pembrolizumab in 1L metastatic Triple Negative Breast Cancer (mTNBC)
